Manalapan, NJ (PRWEB) January 12, 2009
Recent FDA (Food and Drug Administration) warnings have been issued producing consumers conscious of the identified and inherent risks that are associated with utilizing popular dermal fillers and botulism-based facial injections--like Botox. Of the far more severe side effects, the FDA warnings specifically cited respiratory failure and death, alongside a plethora of other, less severe side effects. The FDA also noted that the risks of contracting any side effects from utilizing such age-fighting products was the identical no matter how significantly or how little of the item was being used, nor how typically.
The principal difficulty with botulism-based facial injections, according to the FDA report, is that in some circumstances the botulism can spread and trigger severe damage to the surrounding areas that are not being treated. In a lot of circumstances, the loss of facial expressiveness has been reported, where patients feel a often permanent numbing to the tissues in the surrounding areas, and or the facial muscles.
When it comes to dermal fillers, the side effects that can be associated are similar to those of botulism-based injections. Many patients reported contracting much less serious side effects, such as rashes and infections to the treated areas. In some serious incidents, patients died from adverse side effects. And some dermal fillers injections are even becoming recalled by the FDA, or having to add additional warning labels, because they can leave behind harmful traces in the skin post treatment.
"As more customers are alerted to the associated dangers with making use of well-known age-fighting dermal fillers and botulism-based facial injections to treat the signs of aging, many are choosing to go with a safer route by using successful eye creams like Eyelastin instead," states Lisa Goodwill, spokesperson for Dermagevity Skin Care--a leading cosmeceutical organization.
"We have observed a dramatic rise in the sales of Eyelastin over the past couple of months as far more customers turn into wary of the adverse side effects that are associated with such age-fighting items (facial injections)," says Goodwill. "Our Eyelastin eye cream has been clinically proven to be as efficient as any of the facial injections, but has no identified side effects, and is far far more price successful in the lengthy term for the consumer."
The eye cream, Eyelastin, is applied in little amounts around the skin near the eyes and lightly massaged into the skin one time per day. Results can generally be seen inside the first many weeks of usage. It has been clinically proven to be successful in minimizing the appearances of dark under eye circles, crow's feet, puffy eyes, fine lines and smile lines.
For much more info on Eyelastin eye cream, please visit them online at: http://www.eyelastin.com.
About Eyelastin:
The only eye cream that uses a breakthrough Nanoderm technology, a proprietary ingredient complex that brings together a effective combination of proven anti-aging ingredients with an advanced delivery technologies.
Utilizes a revolutionary new formula that combines Hyaluronic Acid--which can carry up to a thousand times its own weight in water--and Vitamin K, which has been proven to greatly minimize puffiness and wrinkles in the skin
Incorporates clinically-proven, age-fighting ingredients like Palmitoyl Tetrapeptide-7, and Palmitoyl Oligopeptide--which have been proven to promote collagen production and improve the development and the growth of the connective tissues
Minimizes the appearances of dark circles under eyes, puffy eyes and crow's feet, and assists to reverse the effects of aging and the appearance of wrinkles and fine lines in the skin
100% safe, successful and all-natural
Has no recognized adverse side effects
Available on the web for a generous discount on their secured on-line store at: http://www.eyelastin.com
# # #
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
A lot more Botulism Press Releases
No comments:
Post a Comment